Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Inhibikase Therapeutics Inc.
IKT | US
1.89
USD0.01
0.53%
IKT | US
Loading StockChartView...
About Inhibikase Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.89
Open
1.88
High
1.90
Low
1.80
Inhibikase Therapeutics Inc. a clinical-stage pharmaceutical company develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009 a small molecule Abelson tyrosine kinase inhibitor which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics Inc. has research and development collaborations with Johns Hopkins University Arizona State University University of Bordeaux and Michigan State University as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta Georgia.
View LessIKT | US
Risk
73.7
Sharpe
-0.19
Luna's Score
37/100
Recommendation
Sell
Luna says (IKT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
82.4%1 month
73.7%3 months
77.7%6 months
71.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.44
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
0.34
Ent. to rev.
2.75
PEG
-
Other Fundamentals
EBITDA
-18.98M
MarketCap
18.85M
MarketCap(USD)
18.85M
Div. yield
-
Op. margin
-23.89K
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-149.69
Short ratio
2.37
Short perc.
0.67
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.51
Range1M
0.69
Range3M
0.83
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.39
Price X volume
2.45M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.34 | 0.53 | Cheaper |
| Ent. to Revenue | 2.75 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.44 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 77.71 | 72.80 | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 18.85M | 3.66B | Emerging |
